Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Entera Bio Ltd. is a clinical-stage biotechnology company focused on developing orally delivered peptide and protein replacement therapies for diseases with significant unmet medical need. The company operates within the biopharmaceutical and life sciences industries, with a particular emphasis on metabolic and endocrine disorders. Its core objective is to overcome the limitations of injectable biologics by enabling oral administration of large-molecule drugs.
The company’s primary value driver is its proprietary oral drug delivery platform, which is designed to enhance the absorption and bioavailability of biologic compounds that are typically degraded in the gastrointestinal tract. Entera Bio’s lead programs target osteoporosis and other bone-related conditions, positioning the company in a niche segment of the biotechnology market. Founded in 2009, Entera Bio evolved from early-stage formulation research into a publicly traded company, listing its ordinary shares on Nasdaq under the ticker ENTX.
Business Operations
Entera Bio’s operations are organized around research and development of oral biologic formulations rather than commercialized products, as the company does not currently generate product revenue. Its pipeline includes orally delivered peptide candidates based on teriparatide (PTH 1-34) and other biologic molecules, developed using its proprietary delivery technology. Revenue historically has consisted primarily of collaboration payments, licensing arrangements, and research grants rather than product sales.
The company conducts its development activities through in-house research capabilities and outsourced clinical trials, with operations split between Israel and the United States. Entera Bio controls its core formulation technology and intellectual property portfolio and has engaged in selective partnerships with pharmaceutical and academic institutions to advance its pipeline. The company does not report distinct operating segments, reflecting its focused R&D-driven business model.
Strategic Position & Investments
Strategically, Entera Bio aims to position itself as a platform innovator in oral biologics, seeking to unlock new lifecycle and market opportunities for peptide-based drugs. Its growth strategy centers on advancing clinical-stage assets, expanding the applicability of its oral delivery technology, and pursuing strategic collaborations with larger pharmaceutical companies.
Notable investments include sustained capital allocation toward clinical development programs and intellectual property expansion rather than acquisitions of external companies. The company has evaluated additional indications for its oral peptide candidates, including metabolic and gastrointestinal disorders, representing emerging areas of potential growth. Entera Bio does not report ownership of major operating subsidiaries, instead operating primarily through the parent entity.
Geographic Footprint
Entera Bio maintains a geographically concentrated but internationally oriented footprint. Its corporate headquarters and primary research operations are based in Israel, while its U.S. presence supports regulatory, investor relations, and clinical development activities. The company’s shares are publicly traded in the United States on the Nasdaq Capital Market.
Clinical trials and research collaborations involve sites across North America and Europe, reflecting the global nature of its development strategy. While Entera Bio does not have commercial operations, its regulatory and clinical focus is aligned with major pharmaceutical markets, particularly the U.S., which represents its most significant future target market.
Leadership & Governance
Entera Bio is led by an executive team with experience in biotechnology, pharmaceuticals, and clinical development, supported by a board with scientific and industry expertise. The leadership emphasizes disciplined capital management, platform innovation, and strategic partnerships as core elements of its governance philosophy.
Key executives include:
- Miranda Toledano – Chief Executive Officer
- Dr. David Geffen – Founder and Chief Scientific Officer
- Ben Shimon – Chief Financial Officer
- Dr. Jonathan Rosen – Vice President of Research and Development
The company’s governance framework aligns with U.S. public company standards and Israeli corporate law, with oversight focused on clinical progress, regulatory compliance, and long-term shareholder value creation.